Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment

FASEB Journal

Volumn 30, Issue 2, 2016, Pages 994-1001

  Fajol, Abul ^a   Chen, Hong ^a   Umbach, Anja T ^a   Quarles, L Darryl ^b   Lang, Florian ^a   Föller, Michael ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Calcitriol; Propranolol; Protein kinase B; Sympathetic activity

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; GLYCOGEN SYNTHASE KINASE 3; PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROPRANOLOL; VANILMANDELIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBROBLAST GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; MOUSE; NONHUMAN; PHOSPHATE METABOLISM; PHOSPHATE URINE LEVEL; PHOTOMETRY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RAT; SYMPATHETIC TONE; ANIMAL; BIOSYNTHESIS; GENETICS; KIDNEY; METABOLISM; MUTANT MOUSE STRAIN;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTORS; GLYCOGEN SYNTHASE KINASE 3; KIDNEY; MICE; MICE, MUTANT STRAINS; PHOSPHATES; PHOSPHATIDYLINOSITOL 3-KINASES; PROPRANOLOL; VANILMANDELIC ACID;

EID: 84958962587     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.15-279943     Document Type: Article

References (60)

1. Allon, M. (1992) Effects of insulin and glucose on renal phosphate reabsorption: Interactions with dietary phosphate. J. Am. Soc.Nephrol. 2, 1593-1600
2. DeFronzo, R. A., Goldberg,M., and Agus, Z. S. (1976) The effects of glucose and insulin on renal electrolyte transport. J. Clin. Invest. 58, 83-90
3. Hawkins, P. T., Anderson, K. E., Davidson, K., and Stephens, L. R. (2006) Signalling through class I PI3Ks inmammalian cells. Biochem. Soc. Trans. 34, 647-662
4. Lang, F., Böhmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, N., and Vallon, V. (2006) (Patho)physiological significance of the serum-and glucocorticoid-inducible kinase isoforms. Physiol. Rev. 86, 1151-1178
5. Shaw, M., Cohen, P., and Alessi, D.R. (1997) Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 ismediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett. 416, 307-311
6. Sakoda, H., Gotoh, Y., Katagiri, H., Kurokawa, M., Ono, H., Onishi, Y., Anai, M., Ogihara, T., Fujishiro, M., Fukushima, Y., Abe, M., Shojima, N., Kikuchi, M., Oka, Y., Hirai, H., and Asano, T. (2003) Differing roles of Akt and serum-and glucocorticoid-regulated kinase in glucose metabolism, DNA synthesis, and oncogenic activity. J. Biol. Chem. 278, 25802-25807
7. Wyatt, A.W.,Hussain,A.,Amann, K.,Klingel, K.,Kandolf,R., Artunc, F., Grahammer, F.,Huang, D. Y., Vallon, V., Kuhl, D., and Lang, F. (2006)DOCA-induced phosphorylation of glycogen synthase kinase 3beta. Cell. Physiol. Biochem. 17, 137-144
8. Bhandaru,M.,Kempe,D.S., Rotte,A.,Capuano,P., Pathare, G.,Sopjani, M., Alesutan, I., Tyan, L., Huang, D. Y., Siraskar, B., Judenhofer, M. S., Stange,G., Pichler, B. J., Biber, J., Quintanilla-Martinez, L.,Wagner, C. A., Pearce, D., Föller,M., and Lang, F. (2011)Decreased bone density and increased phosphaturia in gene-targeted mice lacking functional serum-and glucocorticoid-inducible kinase 3. Kidney Int. 80, 61-67
9. Kempe, D. S., Ackermann, T. F., Boini, K. M., Klaus, F., Umbach, A. T., Dërmaku-Sopjani, M., Judenhofer, M. S., Pichler, B. J., Capuano, P., Stange, G., Wagner, C. A., Birnbaum,M. J., Pearce, D., Föller, M., and Lang, F. (2010) Akt2/PKBbeta-sensitive regulation of renal phosphate transport. Acta Physiol. (Oxf.) 200, 75-85
10. Föller, M., Kempe, D. S., Boini, K. M., Pathare, G., Siraskar, B., Capuano, P., Alesutan, I., Sopjani, M., Stange, G., Mohebbi, N., Bhandaru, M., Ackermann, T. F., Judenhofer, M. S., Pichler, B. J., Biber, J., Wagner, C. A., and Lang, F. (2011) PKB/SGK-resistant GSK3 enhances phosphaturia and calciuria. J. Am. Soc. Nephrol. 22, 873-880
11. Siraskar, B., Völkl, J., Ahmed, M. S., Hierlmeier, M., Gu, S., Schmid, E., Leibrock, C., Föller, M., Lang, U. E., and Lang, F. (2011) Enhanced catecholamine release in mice expressing PKB/SGKresistant GSK3. Pflugers Arch. 462, 811-819
12. Lu, Y., and Feng, J. Q. (2011) FGF23 in skeletal modeling and remodeling. Curr. Osteoporos. Rep. 9, 103-108
13. Hori, M., Shimizu, Y., and Fukumoto, S. (2011) Minireview: Fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 152, 4-10
14. Marsell, R., and Jonsson, K. B. (2010) The phosphate regulating hormone fibroblast growth factor-23. Acta Physiol. (Oxf.) 200, 97-106
15. Bai, X. Y., Miao, D., Goltzman, D., and Karaplis, A. C. (2003) The autosomal dominant hypophosphatemic rickets R176Qmutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J. Biol. Chem. 278, 9843-9849
16. Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H. S., Jüppner, H., and Jonsson, K. B. (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145, 3087-3094
17. Segawa, H., Kawakami, E., Kaneko, I., Kuwahata, M., Ito, M., Kusano, K., Saito, H., Fukushima, N., and Miyamoto, K. (2003) Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch. 446, 585-592
18. Shimada, T.,Mizutani, S.,Muto, T., Yoneya, T.,Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., and Yamashita, T. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 98, 6500-6505
19. Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., and Yamashita, T. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19, 429-435
20. Shimada, T., Yamazaki, Y., Takahashi,M.,Hasegawa,H.,Urakawa, I., Oshima, T., Ono, K., Kakitani, M., Tomizuka, K., Fujita, T., Fukumoto, S., and Yamashita, T. (2005) Vitamin D receptorindependent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 289, F1088-F1095
21. Andrukhova, O., Slavic, S., Smorodchenko, A., Zeitz, U., Shalhoub, V., Lanske, B., Pohl, E. E., and Erben, R. G. (2014) FGF23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 6, 744-759
22. Spichtig, D., Zhang,H.,Mohebbi,N., Pavik, I., Petzold,K., Stange,G., Saleh, L., Edenhofer, I., Segerer, S., Biber, J., Jaeger, P., Serra, A. L., and Wagner, C. A. (2014) Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int. 85, 1340-1350
23. Gattineni, J., Twombley, K., Goetz, R., Mohammadi, M., and Baum, M. (2011) Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 ismediated by FGF receptors 3 and 4. Am. J. Physiol. Renal Physiol. 301, F371-F377
24. Shimada, T., Kakitani,M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., and Yamashita, T. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitaminDmetabolism. J. Clin. Invest. 113, 561-568
25. Inoue, Y., Segawa, H., Kaneko, I., Yamanaka, S., Kusano, K., Kawakami, E., Furutani, J., Ito,M.,Kuwahata,M., Saito,H.,Fukushima,N.,Kato, S., Kanayama, H. O., and Miyamoto, K. (2005) Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem. J. 390, 325-331
26. Hu,M. C., Shiizaki, K., Kuro-o,M., andMoe,O. W. (2013) Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu. Rev. Physiol. 75, 503-533
27. Kuro-o, M. (2010) Overview of the FGF23-Klotho axis. Pediatr. Nephrol. 25, 583-590
28. Faul, C., Amaral, A. P., Oskouei, B., Hu,M. C., Sloan, A., Isakova, T., Gutiérrez,O.M., Aguillon-Prada,R., Lincoln, J.,Hare, J.M.,Mundel, P.,Morales, A., Scialla, J., Fischer, M., Soliman, E. Z., Chen, J., Go, A. S., Rosas, S. E., Nessel, L., Townsend, R. R., Feldman, H. I., St John Sutton, M., Ojo, A., Gadegbeku, C., Di Marco, G. S., Reuter, S., Kentrup, D., Tiemann, K., Brand, M., Hill, J. A., Moe, O. W., Kuro-O, M., Kusek, J. W., Keane, M. G., and Wolf,M. (2011) FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408
29. Seifert, M. E., De Las Fuentes, L., Ginsberg, C., Rothstein, M., Dietzen, D. J., Cheng, S. C., Ross, W., Windus, D., Dávila-Román, V. G., and Hruska, K. A. (2014) Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. Am. J. Nephrol. 39, 392-399
30. De Jongh, R. T., Vervloet, M. G., Bravenboer, N., Heijboer, A. C., denHeijer, M., and Lips, P. (2013) [Chronic bone pain due to raised FGF23 production? The importance of determining phosphate levels]. Ned. Tijdschr. Geneeskd. 157, A5908
31. Martin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J. Q., and Quarles, L. D. (2011) Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a commonpathway involving FGFreceptor (FGFR) signaling. FASEB J. 25, 2551-2562
32. Quarles, L. D. (2003) FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am. J. Physiol. Endocrinol. Metab. 285, E1-E9
33. Tenenhouse, H. S., and Sabbagh, Y. (2002) Novel phosphateregulating genes in the pathogenesis of renal phosphate wasting disorders. Pflugers Arch. 444, 317-326
34. ADHR Consortium. (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26, 345-348
35. White, K. E., Jonsson, K. B.,Carn,G.,Hampson,G., Spector,T.D., Mannstadt, M., Lorenz-Depiereux, B., Miyauchi, A., Yang, I. M., Ljunggren, O., Meitinger, T., Strom, T. M., J üppner, H., and Econs,M. J. (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J. Clin. Endocrinol. Metab. 86, 497-500
36. Saini, R. K., Kaneko, I., Jurutka, P. W., Forster, R., Hsieh, A., Hsieh, J. C., Haussler, M. R., and Whitfield, G. K. (2013) 1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: Evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif. Tissue Int. 92, 339-353
37. Masuyama, R., Stockmans, I., Torrekens, S., Van Looveren, R., Maes, C., Carmeliet, P., Bouillon, R., and Carmeliet, G. (2006) Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Invest. 116, 3150-3159
38. Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J., and Naveh-Many, T. (2010) PTH increases FGF23 gene expression andmediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 299, F882-F889
39. Rhee, Y., Bivi, N., Farrow, E., Lezcano, V., Plotkin, L. I.,White, K. E., and Bellido, T. (2011) Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49, 636-643
40. Rhee, Y., Allen, M. R., Condon, K., Lezcano, V., Ronda, A. C., Galli, C., Olivos, N., Passeri, G., O'Brien, C. A., Bivi, N., Plotkin, L. I., and Bellido, T. (2011) PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J. Bone Miner. Res. 26, 1035-1046
41. Ferrari, S. L., Bonjour, J. P., and Rizzoli, R. (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90, 1519-1524
42. Perwad, F.,Azam,N., Zhang,M. Y., Yamashita,T.,Tenenhouse,H. S., and Portale, A. A. (2005) Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146, 5358-5364
43. Fournier, C., Rizzoli, R., and Ammann, P. (2014) Low calciumphosphate intakes modulate the low-protein diet-related effect on peak bone mass acquisition: A hormonal and bone strength determinants study in female growing rats. Endocrinology 155, 4305-4315
44. Takashi, Y., and Fukumoto, S. (2015) Bone and nutrition: The relationship between iron and phosphatemetabolism(in Japanese). Clin. Calcium 25, 1037-1042
45. Clinkenbeard, E. L., Farrow, E. G., Summers, L. J., Cass, T. A., Roberts, J. L., Bayt, C. A., Lahm, T., Albrecht, M., Allen, M. R., Peacock,M., andWhite,K.E. (2014)Neonatal irondeficiency causes abnormal phosphatemetabolismby elevating FGF23 in normal and ADHR mice. J. Bone Miner. Res. 29, 361-369
46. Wolf, M., Koch, T. A., and Bregman, D. B. (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J. Bone Miner. Res. 28, 1793-1803
47. Imel, E. A., Peacock, M., Gray, A. K., Padgett, L. R., Hui, S. L., and Econs, M. J. (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J. Clin. Endocrinol. Metab. 96, 3541-3549
48. Farrow, E. G., Yu, X., Summers, L. J., Davis, S. I., Fleet, J. C., Allen, M. R., Robling, A. G., Stayrook, K. R., Jideonwo, V., Magers, M. J., Garringer, H. J., Vidal, R., Chan, R. J., Goodwin, C. B., Hui, S. L., Peacock, M., and White, K. E. (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc. Natl. Acad. Sci. USA 108, E1146-E1155
49. Kawai, M., Kinoshita, S., Shimba, S., Ozono, K., and Michigami, T. (2014) Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. J. Biol. Chem. 289, 1457-1466
50. McManus, E. J., Sakamoto, K., Armit, L. J., Ronaldson, L., Shpiro,N., Marquez, R., and Alessi, D. R. (2005) Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 24, 1571-1583
51. Voelkl, J., Alesutan, I., Leibrock, C. B., Quintanilla-Martinez, L., Kuhn,V.,Feger,M.,Mia, S.,Ahmed,M.S., Rosenblatt,K.P.,Kuro-O, M., and Lang, F. (2013) Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J. Clin. Invest. 123, 812-822
52. Bhattacharyya, N., Wiench, M., Dumitrescu, C., Connolly, B. M., Bugge,T.H.,Patel,H.V., Gafni, R. I.,Cherman,N., Cho,M.,Hager, G. L., and Collins, M. T. (2012) Mechanism of FGF23 processing in fibrous dysplasia. J. Bone Miner. Res. 27, 1132-1141
53. Fakhri, H., Pathare, G., Fajol, A., Zhang, B., Bock, T., Kandolf, R., Schleicher, E., Biber, J., Föller, M., Lang, U. E., and Lang, F. (2014) Regulation of mineral metabolism by lithium. Pflugers Arch. 466, 467-475
54. Boini,K.M.,Amann,K.,Kempe,D.,Alessi,D.R., andLang, F. (2009) Proteinuria in mice expressing PKB/SGK-resistant GSK3. Am. J. Physiol. Renal Physiol. 296, F153-F159
55. Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., Galderisi,M., Grobbee, D. E., Jaarsma, T., Kirchhof, P., Kjeldsen, S. E., Laurent, S., Manolis, A. J., Nilsson, P. M., Ruilope, L. M., Schmieder, R. E., Sirnes, P. A., Sleight, P., Viigimaa, M., Waeber, B., and Zannad, F.; Task Force Members. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for themanagement of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281-1357
56. Yamamoto, K. (2015) b-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. J. Cardiol. 66, 189-194
57. Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., and Kirchhof, P.; ESC Committee for Practice Guidelines (CPG) (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33, 2719-2747
58. Parker, B. D., Schurgers, L. J., Brandenburg, V. M., Christenson, R.H., Vermeer, C., Ketteler,M., Shlipak,M. G., Whooley, M. A., and Ix, J.H. (2010) The associations of fibroblast growth factor 23 and uncarboxylatedmatrix Gla protein withmortality in coronary artery disease: The Heart and Soul Study. Ann. Intern. Med. 152, 640-648
59. Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E., Christenson, R., Wang, T. J., deFilippi, C., and Wolf, M. (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119, 2545-2552
60. Mathew, J. S., Sachs, M. C., Katz, R., Patton, K. K., Heckbert, S. R., Hoofnagle, A. N., Alonso, A., Chonchol, M., Deo, R., Ix, J. H., Siscovick, D. S., Kestenbaum, B., and De Boer, I.H. (2014) Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 130, 298-307